- Home
- DLTH vs ZNTL Comparison
DLTH vs ZNTL Comparison
Compare DLTH & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DLTH
- ZNTL
- Stock Information
- Founded
- DLTH 1989
- ZNTL 2014
- Country
- DLTH United States
- ZNTL United States
- Employees
- DLTH N/A
- ZNTL N/A
- Industry
- DLTH Clothing/Shoe/Accessory Stores
- ZNTL Biotechnology: Pharmaceutical Preparations
- Sector
- DLTH Consumer Discretionary
- ZNTL Health Care
- Exchange
- DLTH Nasdaq
- ZNTL Nasdaq
- Market Cap
- DLTH 121.1M
- ZNTL 118.3M
- IPO Year
- DLTH 2015
- ZNTL 2020
- Fundamental
- Price
- DLTH $2.81
- ZNTL $1.36
- Analyst Decision
- DLTH Buy
- ZNTL Buy
- Analyst Count
- DLTH 1
- ZNTL 6
- Target Price
- DLTH $7.00
- ZNTL $6.53
- AVG Volume (30 Days)
- DLTH 64.5K
- ZNTL 749.6K
- Earning Date
- DLTH 12-04-2025
- ZNTL 11-06-2025
- Dividend Yield
- DLTH N/A
- ZNTL N/A
- EPS Growth
- DLTH N/A
- ZNTL N/A
- EPS
- DLTH N/A
- ZNTL N/A
- Revenue
- DLTH $602,746,000.00
- ZNTL $26,865,000.00
- Revenue This Year
- DLTH N/A
- ZNTL N/A
- Revenue Next Year
- DLTH $0.24
- ZNTL N/A
- P/E Ratio
- DLTH N/A
- ZNTL N/A
- Revenue Growth
- DLTH N/A
- ZNTL N/A
- 52 Week Low
- DLTH $1.58
- ZNTL $1.01
- 52 Week High
- DLTH $4.66
- ZNTL $4.44
- Technical
- Relative Strength Index (RSI)
- DLTH 40.37
- ZNTL 36.38
- Support Level
- DLTH $2.66
- ZNTL $1.49
- Resistance Level
- DLTH $3.06
- ZNTL $1.54
- Average True Range (ATR)
- DLTH 0.20
- ZNTL 0.10
- MACD
- DLTH -0.05
- ZNTL -0.03
- Stochastic Oscillator
- DLTH 20.00
- ZNTL 9.62
About DLTH Duluth Holdings Inc. Class B
Duluth Holdings Inc is an apparel brand in the United States. The company offers shirts, pants, and casual wear for men and women under brands like Alaskan Hardgear, Armachillo, Ballroom, Cab Commander, Crouch Gusset, Dry on the Fly, Duluth Trading Co, Duluthflex, Fire Hose, Longtail T, No Polo Shirt, No Yank, Wild Boar, and others. The Company's revenue consists of the sale of apparel, footwear, and hard goods. The company operates in a single operating segment.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.